MERCK & CO. INC.(NYSE:MRK) stock News

MRK Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill

Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock

7 days ago - By: Chartmill - Mentions: APA STZ EL DECK ...

Explore the top gainers and losers within the S&P500 index in today's session.

2 days ago - By: Benzinga - Mentions: NVAX GSK PFE MRNA

Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens

3 days ago - By: Merck & Co., Inc.

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

3 days ago - By: Zacks Investment Research - Mentions: JNJ LLY ABBV

ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

4 days ago - By: Benzinga - Mentions: NVAX GSK PFE MRNA

Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health'

4 days ago - By: Yahoo Finance - Mentions: VRNA

Here’s How Wall Street is Reacting to Verona Pharma (VRNA)’s Acquisition

4 days ago - By: Zacks Investment Research - Mentions: JNJ

Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

4 days ago - By: Zacks Investment Research - Mentions: AZN PFE

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

4 days ago - By: Zacks Investment Research - Mentions: PFE JNJ LLY

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

4 days ago - By: Zacks Investment Research - Mentions: SNY AZN

Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?

5 days ago - By: Merck & Co., Inc.

Merck to Participate in the 2025 Wells Fargo Healthcare Conference

5 days ago - By: Yahoo Finance

Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances

6 days ago - By: Merck & Co., Inc.

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy

6 days ago - By: MarketBeat - Mentions: IYH PLTR JNJ ABBV ...

As the Market Rotates, This Healthcare ETF Is Leading the Way

6 days ago - By: Zacks Investment Research - Mentions: NVS EXEL

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

6 days ago - By: Zacks Investment Research - Mentions: ANIP CRMD IOVA

IOVA Stock Drops 6% on $350M Common Stock Offering

7 days ago - By: MarketBeat - Mentions: XHB UNH SCHD XLV ...

Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts

7 days ago - By: Zacks Investment Research - Mentions: EXEL

Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?

8 days ago - By: Merck & Co., Inc.

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

10 days ago - By: Zacks Investment Research - Mentions: AZN PFE ABBV

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

11 days ago - By: Chartmill - Mentions: NEM LII PKG IP ...

What's going on in today's session: S&P500 movers

11 days ago - By: Chartmill - Mentions: LII BG PKG IP ...

What's going on in today's session: S&P500 movers

11 days ago - By: The Motley Fool - Mentions: KMB AEP PG NEE ...

Slocum Gordon Exits Stake in Kimberly-Clark Worth Nearly $3 Million

11 days ago - By: Zacks Investment Research

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

13 days ago - By: Zacks Investment Research - Mentions: AZN PFE

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

13 days ago - By: Zacks Investment Research - Mentions: PFE AZN BMY

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

13 days ago - By: Zacks Investment Research - Mentions: MRNA SMMT

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

14 days ago - By: Merck & Co., Inc.

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

14 days ago - By: Zacks Investment Research - Mentions: GILD GSK

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

15 days ago - By: Daiichi Sankyo

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

15 days ago - By: Yahoo Finance - Mentions: OPK

OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics

16 days ago - By: Chartmill

MERCK & CO. INC. (MRK) Stock News

MRK Latest News, Press Relases and Analysis

Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock

Explore the top gainers and losers within the S&P500 index in today's session.

Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health'

Here’s How Wall Street is Reacting to Verona Pharma (VRNA)’s Acquisition

Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?

Merck to Participate in the 2025 Wells Fargo Healthcare Conference

Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy

As the Market Rotates, This Healthcare ETF Is Leading the Way

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

IOVA Stock Drops 6% on $350M Common Stock Offering

Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts

Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

What's going on in today's session: S&P500 movers

What's going on in today's session: S&P500 movers

Slocum Gordon Exits Stake in Kimberly-Clark Worth Nearly $3 Million

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics

MERCK & CO. INC. (NYSE:MRK) – A Strong Value Investment with Undervalued Potential